Moderna Stock Price Prediction 2026, 2030, 2040

Moderna Inc. (NASDAQ: MRNA) has become one of the most closely watched biotech stocks in 2026. This Moderna Stock Price Prediction looks at the company’s current position, recent results, pipeline, major catalysts and long term risks.

Moderna is trying to build a business beyond COVID vaccines. Its pipeline now includes cancer treatments, seasonal vaccines, rare disease programs and other mRNA medicines. The outlook changed sharply in August 2026.

Moderna and Merck reported positive Phase 3 results for their personalized mRNA cancer vaccine in melanoma. The news sent MRNA shares sharply higher. The price targets below are our scenarios. They are not Wall Street targets and should not be treated as guaranteed prices.

Moderna Stock Price Prediction

Nvidia Stock Price Prediction | Tesla Stock Price Prediction

Moderna Stock Price Prediction 2026

Moderna enters the second half of 2026 with a very different story from the one investors saw earlier in the year.

MRNA traded near $63 before the company’s major melanoma announcement. Shares then jumped sharply after Moderna and Merck reported positive Phase 3 results for their personalized cancer vaccine. The stock reached $176.66 during the August 19 session before giving back some of those gains.

Our 2026 scenario puts the average Moderna stock price near $155. A weaker market could push the stock towards $110. A strong continuation of the biotech rally could take MRNA towards $210.

The key issue is whether investors can justify the recent rise with future revenue. The melanoma vaccine still needs regulatory approval. The companies also need to provide more detailed trial data.

Moderna Stock Price Prediction 2027

2027 could become an important year for Moderna.

The company expects several important pipeline developments. Its personalized cancer vaccine could become a major commercial opportunity if regulators approve it and the treatment performs well in wider patient groups.

Moderna is also working on vaccines for flu, COVID and other infectious diseases. The company has said it expects to continue expanding its commercial portfolio.

Our 2027 average price scenario is $180. The downside case is around $120, while a strong commercial and clinical performance could take MRNA towards $250.

Moderna Stock Price Prediction 2028

Moderna’s long term value will depend less on COVID vaccine sales and more on the success of its broader pipeline.

The company had three commercial products at the end of 2025. These included Spikevax, mNEXSPIKE and mRESVIA. Moderna also had a large clinical development pipeline across infectious disease, oncology and rare disease.

Moderna expects to reduce operating expenses and reach targeted cash breakeven in 2028. That makes 2028 an important financial milestone for the company.

Our average price scenario for 2028 is $205. The minimum scenario is $135. A stronger product pipeline could push the stock towards $290.

Moderna Stock Price Prediction 2029

By 2029, investors should have more information about Moderna’s oncology business and its other commercial products.

The biggest question will be whether the company can turn its mRNA technology into several profitable products. Success in cancer could give Moderna a much broader revenue base than its COVID business provided.

Our 2029 average price scenario is $230. MRNA could trade near $150 in a weaker scenario. A strong pipeline and improving financial results could push the stock towards $330.

Moderna Stock Price Prediction 2030

Our Moderna Stock Price Prediction for 2030 remains positive, but the uncertainty is much higher than it is for the next few years.

We estimate an average price of around $260 in 2030. The minimum scenario is $170. A strong long term expansion could take MRNA towards $380.

For this forecast to work, Moderna would need to build several successful products. It would also need to control research costs and generate stronger recurring revenue.

That is possible, but it is not guaranteed.

Moderna Stock Price Prediction 2035

Moderna could have a much larger business by 2035 if its mRNA platform produces successful medicines across several disease areas.

Our 2035 average price scenario is $400. The downside scenario is around $250. A strong product portfolio and successful expansion into cancer and other diseases could push MRNA towards $600.

The cancer program is particularly important. Moderna and Merck are studying the personalized vaccine approach across multiple cancer types. The companies are already running additional trials beyond melanoma.

However, investors should not assume that success in melanoma will automatically translate into success across every cancer. Each indication has its own biology, clinical requirements and commercial challenges.

Moderna Stock Price Prediction 2040

A 2040 stock forecast is highly speculative. The healthcare industry can change significantly over such a long period.

Our long term scenario puts the average Moderna stock price near $500 in 2040. The downside scenario is around $300. If Moderna develops a broad portfolio of successful mRNA medicines, MRNA could potentially reach $750.

This scenario depends on several assumptions. Moderna would need to maintain its scientific advantage, launch successful medicines, manage costs and compete effectively with other biotechnology companies.

Investors should therefore treat the 2040 forecast as a long term scenario rather than a price target.

Why Moderna Stock Is Rising in 2026

The biggest recent catalyst is Moderna’s personalized cancer vaccine.

Moderna and Merck reported positive Phase 3 results for intismeran autogene in patients with high risk melanoma. The treatment was tested alongside Merck’s Keytruda.

The trial met its key goals and showed a significant reduction in the risk of melanoma recurrence and spread. The trial included 1,137 patients. No new safety concerns were reported.

The result changed investor expectations around Moderna’s future. Before the announcement, the company was still heavily associated with declining COVID vaccine sales. The cancer result gave investors a reason to consider Moderna as a broader biotechnology company.

However, the full Phase 3 data has not yet been released. Analysts are still waiting for more information about overall survival, safety and the commercial potential of the treatment.

Moderna Financial Outlook

Moderna reported total revenue of about $1.9 billion for 2025. That was a major decline from the company’s pandemic era revenue. COVID products accounted for most of its product sales in 2025.

The company is now trying to reduce its dependence on COVID vaccines.

For 2026, Moderna continues to expect up to 10% revenue growth. It also reduced its expected operating expense outlook and now expects to finish 2026 with about $4.7 billion to $5.2 billion in cash.

These figures matter because Moderna has been spending heavily on research and development. The company reported a GAAP net loss of about $2.8 billion for 2025.

Moderna Product Pipeline

Moderna is building a broader product portfolio.

Flu Vaccine

Moderna received US FDA approval for its mFlusiva seasonal flu vaccine in August 2026. It became the first mRNA based seasonal flu vaccine approved in the United States. The approval covers adults aged 50 to 64 through traditional approval and adults aged 65 and older through accelerated approval.

COVID Vaccines

Moderna continues to sell Spikevax and mNEXSPIKE. However, COVID vaccine revenue has fallen sharply from its pandemic peak. The company therefore needs newer products to support future growth.

RSV Vaccine

mRESVIA is Moderna’s RSV vaccine. The company launched commercial sales in 2024. Its approved use was later expanded to certain adults aged 18 to 59 who are at increased risk from RSV disease.

Cancer Vaccines

Cancer is now one of the most important parts of Moderna’s long term investment story.

The company is developing personalized mRNA treatments that are designed around mutations found in an individual patient’s tumor. Moderna is working with Merck on several clinical studies involving intismeran autogene.

Moderna Stock Risks

MRNA has significant upside potential, but investors should also understand the risks.

Clinical Trial Risk

Positive results in one trial do not guarantee success in another. Moderna recently reported that its norovirus vaccine candidate did not meet the statistical criteria for early success at a Phase 3 interim analysis. The company plans to enroll an additional cohort.

Regulatory Risk

Every new medicine must pass regulatory review. A delay or rejection could affect Moderna’s future revenue expectations.

High Volatility

MRNA has shown extreme price movements in August 2026. The stock gained 176.97% on August 19 and then fell more than 23% on August 20. It rose again on August 21.

This level of volatility shows why investors should not rely on a single price target.

COVID Revenue Decline

Moderna’s COVID vaccine revenue has fallen sharply since the pandemic period. In 2025, COVID products generated about $1.81 billion in net product sales compared with $3.08 billion in 2024 and $6.67 billion in 2023.

The company therefore needs new products to replace part of that lost revenue.

Is Moderna Stock a Good Investment?

Moderna is an interesting but high risk biotechnology stock.

The company has a valuable mRNA platform and a growing pipeline. Its recent cancer vaccine results have also created a new potential growth story.

At the same time, the stock has already experienced an enormous move. Investors should not assume that strong clinical results automatically make the current valuation attractive.

The biggest question is whether Moderna can turn its scientific progress into sustainable revenue and profit.

For long term investors, Moderna may be worth watching closely. However, MRNA is not a low risk stock.

---

FAQs

What is the Moderna stock price right now?

Moderna closed at about $145.13 on August 21, 2026. The stock has been extremely volatile following the company’s positive cancer vaccine results.

Why did Moderna stock jump in August 2026?

MRNA surged after Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine in melanoma. The treatment met key trial goals and reduced the risk of recurrence and spread when used with Keytruda.

Where Will Moderna Stock Be in 5 Years?

By 2030, Moderna’s stock price could depend heavily on its oncology pipeline and its ability to replace declining COVID revenue. Our base scenario places MRNA near $260 in 2030. A strong product cycle could produce a higher price, while clinical setbacks or weak commercial performance could push the stock much lower.

Where Will Moderna Stock Be in 10 Years?

If Moderna successfully develops several mRNA medicines across cancer, infectious disease and rare disease, the company could become much larger than it is today. Our 2035 scenario puts the average price near $400. However, investors should treat this as a long term scenario rather than a prediction that can be relied upon.

Can Moderna stock reach $200?

Yes, MRNA could reach $200 if investor confidence remains strong and Moderna delivers more positive clinical and commercial results. However, no stock price target is guaranteed.

Can Moderna stock reach $500?

Moderna has traded close to $500 in the past. Reaching $500 again would require strong long term growth from its product pipeline and a much higher company valuation.

Is Moderna stock a good long term investment?

Moderna has strong scientific assets and a broad mRNA pipeline. However, it also faces clinical, regulatory, financial and commercial risks. The stock may suit investors who understand biotechnology risk and can tolerate high volatility.

Does Moderna pay a dividend?

Moderna does not currently pay a regular dividend. The company has focused its cash on research, development, manufacturing and business operations.

What is Moderna’s biggest growth opportunity?

Oncology is one of Moderna’s biggest potential growth areas. Its personalized cancer vaccine with Merck produced positive Phase 3 melanoma results in 2026. The companies are also studying the treatment in other cancers.

---

Disclaimer: This article is for information and educational purposes only. It is not investment advice. Stock prices can move sharply and may fall as well as rise. Long term forecasts are uncertain, especially for biotechnology companies. Always conduct your own research and consider speaking with a qualified financial adviser before making an investment decision.